Inhibikase Therapeutics, Inc. NCM · IKT
Price alert —
Sign in to get a one-time email the moment IKT crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · IKT
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare IKT vs peers
Line IKT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with IKT
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 11 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-03-26 | -0.09 | -0.12 | +23.9% | +3.1% |
| 2025-11-14 | -0.13 | -0.13 | — | -0.7% |
| 2025-08-14 | -0.11 | -0.08 | -37.5% | +2.3% |
| 2025-05-14 | -0.15 | -0.09 | -57.9% | -4.2% |
| 2024-11-14 | -0.65 | -0.48 | -35.4% | -13.1% |
| 2024-08-14 | -0.66 | -0.67 | +1.5% | -5.4% |
| 2024-05-15 | -0.73 | -0.79 | +7.6% | -11.6% |
| 2024-03-27 | -0.64 | -0.85 | +24.7% | -6.1% |
| 2023-11-14 | -0.86 | -1.12 | +23.2% | -4.1% |
| 2023-08-14 | -1.11 | -0.92 | -20.6% | -6.0% |
| 2023-05-15 | -0.96 | -0.90 | -6.7% | -1.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| IKT ★ | $0B | — | -5.7 | — | -4.1 | 2.2 | — | — | — | -4.39% |
| LLY | $1,037B | 41.3 | 25.9 | — | 29.7 | 33.3 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $392B | 32.5 | 19.2 | 0.9 | 17.9 | 3.7 | 19.5% | 0.4% | 61.5% | 5.81% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.6 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 35.6 | 13.2 | — | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $448B | 123.6 | 15.6 | 7.1 | 17.1 | -67.2 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $141B | 18.9 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.75% |
| TMO | $196B | 28.9 | 19.3 | — | 20.9 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 56.89%
| Holder | Shares | % out |
|---|---|---|
| Sands Capital Alternatives, LLC | 13,018,965 | 9.86% |
| Soleus Capital Management, L.P. | 10,875,000 | 8.24% |
| Fairmount Funds Management LLC | 8,625,000 | 6.53% |
| Trails Edge Capital Partners, LP | 8,057,345 | 6.10% |
| Adar1 Capital Management, LLC | 6,606,572 | 5.00% |
| Blackrock Inc. | 6,303,433 | 4.77% |
| Blackstone Inc | 5,938,276 | 4.50% |
| Siren, L.L.C. | 5,850,000 | 4.43% |
| Commodore Capital Lp | 5,397,488 | 4.09% |
| Vanguard Capital Management LLC | 4,450,665 | 3.37% |
Insider activity · 90d
No insider trades for IKT in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-14 | 8-K | view · |
| 4 | 2026-06-30 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 8-K | 2026-06-29 | 8-K | view · |
| 10-Q | 2026-05-12 | 10-Q | view · |
| 8-K | 2026-05-12 | 8-K | view · |
| DEF 14A | 2026-04-30 | DEF 14A | view · |
| 8-K | 2026-04-07 | 8-K | view · |
| 10-K | 2026-03-26 | 10-K | view · |
| 8-K | 2026-03-26 | 8-K | view · |
| 4 | 2026-02-24 | 4 | view · |
| 4 | 2026-02-24 | 4 | view · |
| 4 | 2026-02-24 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 8-K | 2025-12-19 | 8-K | view · |
| 4 | 2025-11-24 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-11-21 | 8-K | view · |
| 8-K | 2025-11-20 | 8-K | view · |
| 10-Q | 2025-11-14 | 10-Q | view · |
| 8-K | 2025-11-14 | 8-K | view · |
| 4 | 2025-08-28 | 4 | view · |
| 10-Q | 2025-08-14 | 10-Q | view · |
| 8-K | 2025-08-14 | 8-K | view · |
| 4 | 2025-07-02 | 4 | view · |
| 4 | 2025-07-02 | 4 | view · |
| 4 | 2025-07-02 | 4 | view · |
| 4 | 2025-07-02 | 4 | view · |
| 4 | 2025-07-02 | 4 | view · |
| 4 | 2025-07-02 | 4 | view · |
| 8-K | 2025-06-30 | 8-K | view · |
| 10-Q | 2025-05-14 | 10-Q | view · |
| 8-K | 2025-05-14 | 8-K | view · |
| DEF 14A | 2025-05-12 | DEF 14A | view · |
| 4 | 2025-04-16 | 4 | view · |
| 8-K | 2025-04-14 | 8-K | view · |
| 10-K | 2025-03-27 | 10-K | view · |
| 8-K | 2025-03-27 | 8-K | view · |
| 4 | 2025-02-25 | 4 | view · |
| 4 | 2025-02-25 | 4 | view · |
| 4 | 2025-02-25 | 4 | view · |
| 8-K | 2025-02-24 | 8-K | view · |
| 4 | 2025-02-19 | 4 | view · |
| 4 | 2025-02-19 | 4 | view · |
| 4 | 2025-02-19 | 4 | view · |
| 4 | 2025-02-19 | 4 | view · |
| 4 | 2025-02-19 | 4 | view · |
| 4 | 2025-02-19 | 4 | view · |
| 4 | 2025-02-19 | 4 | view · |
| 8-K | 2025-02-18 | 8-K | view · |
| 8-K | 2025-01-29 | 8-K | view · |
| 4 | 2025-01-22 | 4 | view · |
| 4 | 2025-01-22 | 4 | view · |
| 4 | 2025-01-22 | 4 | view · |
| 4 | 2025-01-22 | 4 | view · |
About IKT
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot…
Options picks · IKT
ITM + OTM ideas from the latest scanLoading…
Congress trades · IKT
STOCK Act disclosuresLoading…
SEC filings & insiders · IKT
EDGAR · liveLoading…
Holders · IKT
Institutions & insider activityLoading…